Journals / Dicle Tıp Dergisi / 2011 / Cilt: 38 - Sayı: 1

Anti-CagA positivity in duodenal ulcer and functional dyspepsia patients infected with Helicobacter pylori and its effect on the outcome of eradication treatment

Helicobakter pilori ile enfekte duodenal ülser ve fonksiyonel dispepsi hastalarında anti-CagA pozitifliği ve eradikasyon tedavi başarısına etkisi

Pages
7–11
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The titres of serum anti-CagA antibodies may be used in the prediction of eradication outcome, and the modification of eradication therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: CagA positive H. pylori strains are considered to be more virulent than other strains.
📊
Key Findings & Data:In this study, we aimed to investigate the rate of CagA positivity in duodenal ulcer (DU) and functional dyspepsia (FD), and its effect on H. pylori eradication response.
💡
Conclusion & Impact:The titres of serum anti-CagA antibodies may be used in the prediction of eradication outcome, and the modification of eradication therapy.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: CagA positive H. pylori strains are considered to be more virulent than other strains. In this study, we aimed to investigate the rate of CagA positivity in duodenal ulcer (DU) and functional dyspepsia (FD), and its effect on H. pylori eradication response. Materials and methods: The study was performed on H. pylori positive 60 patients with DU and 50 patients with FD, who underwent upper gastrointestinal endoscopy. H. pylori infection was identified by histology. All patients received a quadriple therapy consisted of esomeprazole 20 mg b.i.d., colloidal bismuth subcitrate 600 mg b.i.d., tetracycline 500 mg q.i.d. and metronidazole 500 mg t.i.d. for 7 days. H.pylori status was rechecked using C14-urea breath test 6 weeks after the end of treatment to confirm cure. Specific IgG antibodies for CagA status were determined by enzyme linked immunosorbent assay. Results: CagA positivities in the patients with DU and FD were calculated respectivily 70% and 68% (P>0.05). H. pylori was eradicated in 85.5% of the patients infected with CagA (+) strains, in 50% of those infected with CagA (-) strains (P=0.001). The eradication rates were 95.2% and 55.6% in CagA positive and negative DU subgroups (P=0.001), and 73.5% and 43.8% in CagA positive and negative FD subgroups (P=0.04). Conclusion: CagA positivities were not different in duodenal ulcer and functional dyspepsia. CagA (+) strains was susceptible to the eradication treatment. The titres of serum anti-CagA antibodies may be used in the prediction of eradication outcome, and the modification of eradication therapy.

Özet

olduğu kabul edilmektedir. Bu çalışmada duodenal ülser (DÜ) ve fonksiyonel dispepsi (FD) hastalarında CagA pozitiflik prevalansını ve CagA pozitifliğinin eradikasyon tedavisine etkisini araştırmayı amaçladık. Gereç ve yöntem: Çalışma, üst gastrointestinal endoskopi yapılan H.pilori pozitif 60 DÜ ile 50 FD hastasında gerçekleştirildi. H. pilori durumu histoloji yöntemiyle belirlendi. Hastaların tamamına esomeprozol 20 mg 2x1, kolloidal bizmut subsitrat 300 mg 2x2, metronidazol 500 mg 3x1, tetrasiklin 500 mg 4x1 oluşan dörtlü tedavi 1 hafta süreyle verildi. Eradikasyon kontrolü, tedavi bitiminden 6 hafta sonra C-14 üre nefes testiyle yapıldı. Serum anti-CagA Ig G antikor titreleri, ELISA yöntemiyle çalışıldı. Bulgular: CagA pozitifliği duodenal ülser ve fonksiyonel dispepsi hastalarında sırasıyla % 70 ve % 68 bulundu (P>0.05). CagA pozitif ve negatif hastalarda H. pilori eradikasyon oranları % 85.5 ve % 50 idi (P=0.001). DÜ hastalarının CagA pozitif ve negatif alt gruplarında eradikasyon oranları % 95.2 ve % 55.6 oldu (P=0.001). FD hastalarının CagA durumları pozitif olanlarında % 73.5, negatif olanlarında % 43.8 eradikasyon oranları sağlandı (P=0.04). Sonuç: CagA prevalansı, duodenal ülser hastalarında fonksiyonel dispepsi hastalarından farklı bulunmadı. CagA pozitif suşlar, eradikasyon tedavisine daha duyarlıdır. Serolojik anti-CagA pozitifliği, tedavi cevabını öngörmekte ve tedaviyi modifiye etmekte kullanılabilir.

🔖

Cite This Article

DOĞAN, E., KEFELİ, A., NAZLIGÜL, Y., YENİOVA, A. Ö., KÜÇÜKAZMAN, M., ÇİZMECİ, Z., GÜREŞÇİ, S., FİDAN, C. (2011). Anti-CagA positivity in duodenal ulcer and functional dyspepsia patients infected with Helicobacter pylori and its effect on the outcome of eradication treatment. Dicle Tıp Dergisi, Cilt: 38 - Sayı: 1, 7–11. https://ajindex.com/articles/349776

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Clyne M, Dolan B, Reeves EP. Bacterial factors that mediate colonization of the stomach and virulence of Helicobacter pylori. FEMS Microbiol Lett 2007; 268: 135-143
  2. Jang S, Jones KR, Olsen CH et al. Epidemiological link between gastric disease and polymorphisms in vacA and cagA. J Clin Microbiol 2010; 48: 559-567
  3. Brown LM. Helicobacter pylori: epidemiology and routes of transmission. Epidemiol Rev 2000; 22: 283-297
  4. Beswick EJ, Suarez G, Reyes VE. H pylori and host interactions that influence pathogenesis. World J Gastroenterol 2006; 12: 5599-5605 5. Yılmaz M, Aydın A. Ungan M. et al. The relationship between cagA positivity and serum gastrin and TNF- alpha levels in patients with chronic active gastritis and duodenal ulcer associated with Helicobacter pylori. Turk J Gastroenterol 1999; 10: 385-390
  5. Saruç M, Demir MA, Küçükmetin N, et al. Predictive value of tissue cagA status in Helicobacter pylori infection. Turk J Gastroenterol 2001; 12: 27-31
  6. Ağbaba E, Nazlıgül Y, Yeniova AÖ, ve ark. Helikobakter pirli eradikasyonunun fonksiyonel dispepsi sendromları üzerine kısa dönem etkileri. Dicle Tıp Derg 2010;37:211-216
  7. Go MF, Graham DY. Presence of the cagA gene in the majority of Helicobacter pylori strains is independent of whether the individual has duodenal ulcer or asymptomatic gastritis. Helicobacter 1996; 1: 107-111
  8. Pan ZJ, van der Hulst RW, Feller M, et al. Equally high prevalences of infection with cagA-positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis-associated dyspepsia. J Clin Microbiol 1997; 35: 1344-1347
  9. Ali M, Khan AA, Tiwari SK, Ahmed N, Rao LV, Habibullah CM. Association between cag-pathogenicity island in Helicobacter pylori isolates from peptic ulcer, gastric carcinoma, and non-ulcer dyspepsia subjects with histological changes. World J Gastroenterol 2005; 11: 6815-6822
  10. Peters TM, Owen RJ, Slater E, Varea R, Teare EL, Saverymuttu S. Genetic diversity in the Helicobacter pylori cag pathogenicity island and effect on expression of anti-CagA serum antibody in UK patients with dyspepsia. J Clin Pathol 2001;54:219-223
  11. Wang Y, Luo YH, Yan J. Detection of cagA gene, CagA protein in Helicobacter pylori isolates and its antibody in serum of patients with gastric diseases by a recombinant protein CagA 1. Zhejiang Da Xue Xue Bao Yi Xue Ban 2005;34:223-229
  12. Kumar S, Dhar A, Srinivasan S, Jain S, Rattan A, Sharma MP. Antibodies to CagA protein are not